Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Neupro rotigotine: Phase III data

In an open-label extension of the double-blind Phase III SP 512 trial, dyskinesia

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE